DexCom, Inc.
DXCM · Nasdaq
- $83.03
- $31.95B
- Open
- —
- —
- $83.76 - $84.98
- $54.11 - $92.59
- —
- —
- 2.54M
About DexCom, Inc.
DexCom sells continuous glucose monitoring systems that track glucose levels and support diabetes management. It makes money primarily by selling these CGM systems into a market influenced by reimbursement access, with demand from users managing diabetes and the healthcare channels that provide access to them. The supplied evidence does not provide a separately quantified segment mix; the disclosed business discussion is concentrated on CGM demand, broader coverage and market-share gains. DexCom generated $4.7 billion of revenue and $0.8 billion of net income in fiscal 2025, up from $4.0 billion and $0.6 billion, respectively, in fiscal 2024.
Notable Price Movement
- Aug 3-7$84.751.56%
DexCom rose $12.09, or 16.15%, from $74.85 to $86.94 over the period, with nearly all of the gain arriving after its second-quarter update. Shares jumped 11.9% on July 31 to $83.45 on heavy volume after DexCom reported a Q2 earnings and revenue beat, 13% year-over-year revenue growth, rising margins and stronger 2026 guidance, supported by demand, reimbursement expansion and share gains. The stock added another 4.6% on August 3, briefly reaching $87.31 and moving above the cited $86.11 average analyst target. It then edged down 0.4% on August 4. Broader technology strength, including gains tied to Amazon earnings, provided a supportive market backdrop but was secondary to the company-specific earnings reaction.
